Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.54 |
| ▸ | TERT | O14746 | 3/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.49 |
| ▸ | PPARG | P37231 | 3/20 | 0.49 |
| ▸ | PPARD | Q03181 | 3/20 | 0.49 |
| ▸ | PPARA | Q07869 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | BLM | P54132 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | FABP4 | P15090 | 2/20 | 0.49 |
| ▸ | GMNN | O75496 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | APEX1 | P27695 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30361054 | 1.00 | FAAH (0.57) | FAAHSMN1; SMN2SLC6A5TERTPTPN1 | |
| SCHEMBL17079548 | 1.00 | FAAH (0.57) | FAAHSMN1; SMN2SLC6A5TERTPTPN1 | |
| SCHEMBL29425333 | 1.00 | FAAH (0.57) | FAAHSMN1; SMN2SLC6A5TERTPTPN1 | |
| SCHEMBL17079549 | 1.00 | FAAH (0.57) | FAAHSMN1; SMN2SLC6A5TERTPTPN1 | |
| SCHEMBL17079545 | 1.00 | FAAH (0.57) | FAAHSMN1; SMN2SLC6A5TERTPTPN1 | |
| SCHEMBL30361055 | 1.00 | FAAH (0.57) | FAAHSMN1; SMN2SLC6A5TERTPTPN1 | |
| SCHEMBL17079547 | 1.00 | FAAH (0.57) | FAAHSMN1; SMN2SLC6A5TERTPTPN1 | |
| SCHEMBL20529761 | 0.98 | FAAH (0.55) | FAAHSMN1; SMN2SLC6A5TERTPTPN1 | |
| SCHEMBL20529769 | 0.98 | FAAH (0.55) | FAAHSMN1; SMN2SLC6A5TERTPTPN1 | |
| SCHEMBL20529780 | 0.98 | FAAH (0.55) | FAAHSMN1; SMN2SLC6A5TERTPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4619021-A1 | HER RECEPTOR DERIVED PEPTIDES AND METHODS OF USE THEREOF | Ramot at Tel-Aviv University Ltd. (IL) | 2025-09-24 | — | — | EP | claimed |
| CN-112119085-B | Stabilizing peptide-mediated targeted protein degradation | 丹娜-法伯癌症研究院有限公司 | 2025-04-01 | — | — | CN | claimed |
| WO-2025027389-A1 | BIOLOGICALLY ACTIVE COMPOUNDS COMPRISING A STAPLED OR STITCHED PEPTIDE | SUTURA THERAPEUTICS LIMITED (GB) | 2025-02-06 | — | — | WO | claimed |
| WO-2024105656-A1 | HER RECEPTOR DERIVED PEPTIDES AND METHODS OF USE THEREOF | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2024-05-23 | — | — | WO | claimed |
| WO-2024069229-A2 | BIOLOGICALLY ACTIVE COMPOUNDS | SUTURA THERAPEUTICS LTD (GB) | 2024-04-04 | — | — | WO | claimed |
| US-11944688-B2 | Biologically active compounds | SUTURA THERAPEUTICS LTD (GB) | 2024-04-02 | — | — | US | claimed |
| WO-2024054892-A1 | THERAPEUTIC PEPTIDES | SHAPE THERAPEUTICS INC. (US) | 2024-03-14 | — | — | WO | claimed |
| US-20230158166-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | SUTURA THERAPEUTICS LTD (GB) | 2023-05-25 | — | — | US | claimed |
| US-11541124-B2 | Biologically active compound conjugated to a stapled or stitched peptide | SUTURA THERAPEUTICS LTD (TC) | 2023-01-03 | — | — | US | claimed |
| US-20220169688-A1 | SELECTIVE TARGETING OF UBIQUITIN- AND UBIQUITIN-LIKE E1-ACTIVATING ENZYMES BY STRUCTURALLY-STABILIZED PEPTIDES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-06-02 | — | — | US | claimed |
| CN-114026113-A | Selective targeting of ubiquitin and ubiquitin-like E1 activating enzymes by structurally stabilized peptides | 丹娜法伯癌症研究院 | 2022-02-08 | — | — | CN | claimed |
| US-20210324029-A1 | STABLE MODULATORS OF GAMMA-C-CYTOKINE ACTIVITY | Bioniz Therapeutics, Inc. | 2021-10-21 | — | — | US | claimed |
| EP-3737404-A1 | SELECTIVE TARGETING OF APOPTOSIS PROTEINS BY STRUCTURALLY-STABILIZED AND/OR CYSTEINE-REACTIVE NOXA PEPTIDES | Dana Farber Cancer Institute, Inc. (US) | 2020-11-18 | — | — | EP | claimed |
| US-20200353092-A1 | BIOLOGICALLY ACTIVE COMPOUND CONJUGATED TO A STAPLED OR STITCHED PEPTIDE | SUTURA THERAPEUTICS LTD (TC) | 2020-11-12 | — | — | US | claimed |
| WO-2020215005-A1 | SELECTIVE TARGETING OF UBIQUITIN- AND UBIQUITIN-LIKE E1-ACTIVATING ENZYMES BY STRUCTURALLY-STABILIZED PEPTIDES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-22 | — | — | WO | claimed |
| US-10774114-B2 | Respiratory syncytial virus (RSV) replication inhibitors | FONDATION THE ARK (CH) | 2020-09-15 | — | — | US | claimed |
| EP-3606940-A1 | STABLE MODULATORS OF GAMMA-C-CYTOKINE ACTIVITY | Bioniz, LLC (US) | 2020-02-12 | — | — | EP | claimed |
| WO-2019118719-A1 | SELECTIVE TARGETING OF APOPTOSIS PROTEINS BY STRUCTURALLY-STABILIZED AND/OR CYSTEINE-REACTIVE NOXA PEPTIDES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-06-20 | — | — | WO | claimed |
| WO-2018187499-A1 | STABLE MODULATORS OF GAMMA-C-CYTOKINE ACTIVITY | BIONIZ, LLC (US) | 2018-10-11 | — | — | WO | claimed |
| WO-2018170299-A1 | INHIBITORS OF PROKARYOTIC GENE TRANSCRIPTION AND USES THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2018-09-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11541124-B2 | Biologically active compound conjugated to a stapled or stitched peptide | BPGM, TMPO, SLC7A1 | FAAH 4570/4885SMN1; SMN2 473/4885SLC6A5 449/4885 |
| US-20200353092-A1 | BIOLOGICALLY ACTIVE COMPOUND CONJUGATED TO A STAPLED OR STITCHED PEPTIDE | BPGM, TMPO, SLC7A1 | FAAH 4569/4885SMN1; SMN2 469/4885SLC6A5 448/4885 |
| US-11944688-B2 | Biologically active compounds | BPGM, PICALM, TMPO | FAAH 4637/4885SMN1; SMN2 623/4885SLC6A5 390/4885 |
| US-20220169688-A1 | SELECTIVE TARGETING OF UBIQUITIN- AND UBIQUITIN-LIKE E1-ACTIVATING ENZYMES BY STRUCTURALLY-STABILIZED PEPTIDES | UBE2E1, MDM2, UBA1 | FAAH 1879/4885SMN1; SMN2 1547/4885SLC6A5 4702/4885 |
| US-20230158166-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | BPGM, PICALM, TMPO | FAAH 4637/4885SMN1; SMN2 623/4885SLC6A5 390/4885 |
| US-20210324029-A1 | STABLE MODULATORS OF GAMMA-C-CYTOKINE ACTIVITY | IL2, IL2RA, GMFG | FAAH 4632/4885SMN1; SMN2 1305/4885SLC6A5 4338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.